Head to Head Review: RAPT Therapeutics (NASDAQ:RAPT) vs. Arbutus Biopharma (NASDAQ:ABUS)


Share on StockTwits

RAPT Therapeutics (NASDAQ:RAPT) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Institutional & Insider Ownership

58.0% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 31.0% of RAPT Therapeutics shares are owned by insiders. Comparatively, 6.7% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for RAPT Therapeutics and Arbutus Biopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RAPT Therapeutics 0 0 6 0 3.00
Arbutus Biopharma 0 1 5 0 2.83

RAPT Therapeutics currently has a consensus price target of $41.33, indicating a potential upside of 103.61%. Arbutus Biopharma has a consensus price target of $6.50, indicating a potential upside of 60.89%. Given RAPT Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe RAPT Therapeutics is more favorable than Arbutus Biopharma.

Profitability

This table compares RAPT Therapeutics and Arbutus Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RAPT Therapeutics N/A -96.05% -44.94%
Arbutus Biopharma -1,163.48% N/A -59.66%

Earnings and Valuation

This table compares RAPT Therapeutics and Arbutus Biopharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RAPT Therapeutics N/A N/A -$43.00 million ($9.89) -2.05
Arbutus Biopharma $6.01 million 57.08 -$153.72 million ($1.62) -2.49

RAPT Therapeutics has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

RAPT Therapeutics beats Arbutus Biopharma on 9 of the 12 factors compared between the two stocks.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.